Relay Therapeutics (RLAY) Receivables - Net (2020 - 2023)

Relay Therapeutics (RLAY) has 4 years of Receivables - Net data on file, last reported at $211000.0 in Q3 2023.

• On a quarterly basis, Receivables - Net fell 95.69% year-over-year to $211000.0 in Q3 2023; TTM through Sep 2023 was $211000.0, a 95.69% decrease from a year earlier, with the FY2022 full-year figure at $306000.0, down 93.26% from the prior year.
• Receivables - Net for Q3 2023 stood at $211000.0, up from $78000.0 in the prior quarter.
• Over the last five years, Receivables - Net for RLAY reached as high as $75.0 million in Q4 2020 and fell as low as $78000.0 in Q2 2023.
• Historically, Receivables - Net has averaged $9.3 million across 4 years, with a median of $4.4 million in 2021.
• Across the five-year window, Receivables - Net rose 15.27% in 2022 and slumped 95.69% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $75.0 million in 2020, then tumbled by 93.95% to $4.5 million in 2021, then sank by 93.26% to $306000.0 in 2022, then sank by 31.05% to $211000.0 in 2023.
• Per Business Quant data, the three most recent Receivables - Net figures were $211000.0 in Q3 2023, $78000.0 in Q2 2023, and $4.9 million in Q1 2023.